<code id='0F68537CFD'></code><style id='0F68537CFD'></style>
    • <acronym id='0F68537CFD'></acronym>
      <center id='0F68537CFD'><center id='0F68537CFD'><tfoot id='0F68537CFD'></tfoot></center><abbr id='0F68537CFD'><dir id='0F68537CFD'><tfoot id='0F68537CFD'></tfoot><noframes id='0F68537CFD'>

    • <optgroup id='0F68537CFD'><strike id='0F68537CFD'><sup id='0F68537CFD'></sup></strike><code id='0F68537CFD'></code></optgroup>
        1. <b id='0F68537CFD'><label id='0F68537CFD'><select id='0F68537CFD'><dt id='0F68537CFD'><span id='0F68537CFD'></span></dt></select></label></b><u id='0F68537CFD'></u>
          <i id='0F68537CFD'><strike id='0F68537CFD'><tt id='0F68537CFD'><pre id='0F68537CFD'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:5878
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          How Brent Saunders' Allergan experiment failed
          How Brent Saunders' Allergan experiment failed

          Allergan,DomSmith/STATItwasn’tsupposedtoworkoutthiswayforBrentSaunders.Fouryearsago,Saunderswasthewh

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          How faith leaders like me can help address America's obesity epidemic

          AdobeManyfactorsdriveAmerica’sobesityepidemic—environment,genetics,eatinghabits,andmore.Solvingthepr